Human chorionic gonadotropin is a 237-amino-acid glycoprotein hormone made by the placenta, and in men it does one thing that matters: it binds the same receptor as luteinising hormone (LH) and tells the testes to make testosterone. That single action is why it shows up in three very different places — an approved treatment for a pituitary disorder, a common add-on to testosterone therapy, and a fertility-recovery tool after anabolic steroid use. This page sets out what each rests on.
The full harms record is on our hCG side effects page, the label's dose tables and units on our hCG dosage page, and the comparison with the pituitary-signal peptide clinics often substitute on our gonadorelin vs hCG page. What hCG is, in plain terms, is in Peptide Lexicon's hCG entry. Nothing here is a recommendation.
What the label approves for men
The current Fresenius Kabi label (DailyMed, effective 11 April 2025, read 20 October 2026) lists three indications. Two concern males:
- Prepubertal cryptorchidism not due to anatomical obstruction — undescended testes in boys, usually treated between ages four and nine.
- Selected cases of hypogonadotropic hypogonadism in males — low testosterone because the pituitary does not send LH. hCG substitutes for the missing signal.
The label's two regimens for the second use, reported as label text: 500–1,000 USP units three times a week for three weeks then twice a week for three weeks; or 4,000 USP units three times weekly for six to nine months, then 2,000 units three times weekly for three more months. The label introduces both as regimens "advocated by various authorities", and says the choice depends on indication, age, weight and "the physician's preference" — wording our dosage page discusses.
What is not on the label: low testosterone from ageing or from testicular failure (primary hypogonadism, where the testes cannot respond), and any use alongside testosterone therapy. In primary hypogonadism hCG has nothing to work on: the signal is already high and the testes are not answering it.
Who sells it
Drugs@FDA (openFDA, data of 16 October 2026) lists three US chorionic gonadotropin applications with a product marketed by prescription: Pregnyl (Organon, BLA017692), Ferring's Novarel and generic chorionic gonadotropin (BLA017016), and Fresenius Kabi (BLA017067). All are urine-derived and given by intramuscular injection. Since 23 March 2020, hCG has been regulated as a biological product, which ended routine pharmacy compounding of it from bulk powder; that transition is set out on our hCG side effects page. The recombinant form, Ovidrel (EMD Serono, BLA021149), is a separate application.
The TRT-adjunct use: what it rests on
Testosterone therapy suppresses the pituitary's LH and FSH, and with them the testes' own output. Testicular testosterone — about 80 times the blood level in healthy men, by our arithmetic from the 2005 study's baseline (serum 1.2% of the testicular level) — falls, and sperm production with it. hCG is added to replace the missing LH signal. The evidence is smaller than the practice:
| Study | Who | hCG regimen | What was measured | Result |
|---|---|---|---|---|
| Coviello 2005, randomised | 29 healthy men on testosterone enanthate 200 mg/week, 3 weeks | Placebo, 125, 250 or 500 IU every other day | Testosterone in testicular fluid (needle aspiration) | Placebo arm suppressed 94%; 125 IU −25%, 250 IU −7%, 500 IU +26% vs baseline |
| Hsieh 2013, chart review | 26 hypogonadal men, mean age 35.9 | 500 IU IM every other day with gel or injections | Hormones, semen, pregnancies | Serum T 207 → 1,056 ng/dL; semen unchanged; 0 azoospermic; 9 partner pregnancies |
| Wenker 2015, case series | 49 men azoospermic or <1 million/mL after testosterone | 3,000 units every other day + other agents | Return of sperm | 47 (95.9%), mean 4.6 months |
| Smit 2025, case series | 19 men still using non-prescribed androgens | hCG, 3–6 months | Total motile sperm count | 1.1 → 66.9 million; normal counts 5% → 58% |
Sources: PMID 15713727, 23260550, 25904023, 40620361, abstracts read 20 October 2026.
Read together, the table shows a consistent direction and a thin base. The one randomised study ran three weeks in healthy volunteers and measured a hormone inside the testes, not fertility. The others are retrospective records from specialist clinics without a comparison group, so they cannot say how many men would have recovered on time alone. The 2025 Dutch series came from a harm-reduction clinic and was funded by Doping Authority Netherlands. The clinic dose range that appears in search results for "hCG for men" — a few hundred IU two to three times a week — matches the doses used in the first two studies, not the label's regimens.
The American Urological Association's testosterone-deficiency guideline (published 2018, validity confirmed 2024; Mulhall et al., PMID 29601923) includes statements for men who want to preserve fertility. The statement text sits behind the association's member login and is not quoted here.
Fertility and recovery after testosterone
The fertility case is the strongest part of the record because the outcome — sperm returning — is concrete. Testosterone therapy causes azoospermia in about 40% of men, according to the background of the 2013 review. In the 2015 series, men with that problem recovered at a mean of 4.6 months on hCG with clomiphene, tamoxifen, anastrozole or FSH, chosen by the treating physician; no one stopped for side effects. The authors called it "an early report of the feasibility" and said comparison with simply stopping testosterone was still needed. hCG compared with clomiphene, a non-peptide alternative, is on our enclomiphene and kisspeptin comparison and our peptides and testosterone page.
Side effects in men
The label's adverse-reaction list is short and old: headache, irritability, restlessness, depression, fatigue, oedema, precocious puberty (in boys), gynecomastia and injection-site pain. Gynecomastia follows from the mechanism: more testicular testosterone also means more oestradiol, which the 2013 review saw rise (not significantly) on combined therapy. The label advises caution in heart or kidney disease, epilepsy, migraine and asthma because androgens can cause fluid retention, and warns that hCG interferes with LH blood tests. The adult-male gap in the safety data is covered on our side effects page.
What the record does not contain
- A randomised trial of hCG with testosterone therapy measuring fertility, testicular size, mood or sexual function.
- A head-to-head trial of hCG against clomiphene or enclomiphene for keeping fertility on testosterone.
- An approved use of hCG for age-related low testosterone, for body composition, or alongside testosterone therapy.
- Long-term safety data in adult men on years of combined therapy.
A urologist or endocrinologist decides whether hCG fits an individual case, at what dose, and with what monitoring.
Sources and dates
Read 20 October 2026: Fresenius Kabi chorionic gonadotropin label (openFDA label record, set f93b2baa-03ac-4650-b35a-20b818d712d6, effective 2025-04-11); openFDA Drugs@FDA records for BLA017692, BLA017016, BLA017067 and BLA021149 (data of 2026-10-16); PubMed abstracts of PMIDs 15713727, 23260550, 25904023, 40620361 and 29601923; the AUA guideline landing page (full text not accessible).